Oneta Carl M, Dufour Jean-François
Division of Gastroenterology, University Hospital of Bern (Inselspital), Switzerland.
Swiss Med Wkly. 2002 Sep 7;132(35-36):493-505. doi: 10.4414/smw.2002.10001.
NASH is a frequent liver disease that develops in close association with IR and may progress to cirrhosis. Exclusion of excessive alcohol consumption as well as of other liver diseases and liver histology are required for diagnosis. Progress in the understanding of the pathophysiology of NASH allows interesting therapeutic considerations. It is logical to treat the associated metabolic conditions to influence the disease activity and progression. In view of promising preliminary data, several drugs are currently used in clinical trials.
非酒精性脂肪性肝炎（NASH）是一种常见的肝脏疾病，与胰岛素抵抗（IR）密切相关，且可能进展为肝硬化。诊断时需要排除过量饮酒以及其他肝脏疾病，并进行肝脏组织学检查。对NASH病理生理学认识的进展带来了有趣的治疗思路。治疗相关的代谢状况以影响疾病活动和进展是合理的。鉴于有前景的初步数据，目前有几种药物正在进行临床试验。
